Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kirby, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents?

Mike Kirby

The Surgery, Nevells Road, Letchworth, SG6 4TS, UK, kirbym{at}globalnet.co.uk

The blood pressure arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) compared treatment with atenolol and bendroflumethiazide against amlodipine and perindopril. This trial has been terminated early due to the emergence of significant benefits in the latter arm. Preliminary data from this trial, presented at the American College of Cardiology's 2005 meeting, are summarised and their implications for UK clinical practice are discussed.

Key Words: hypertension • ASCOT • atenolol • amlodipine • cardiovascular disease.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 2, 100-102 (2005)
DOI: 10.1177/14746514050050020801
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. W Mccallum and M. Fisher
From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 218 - 225.
[Abstract] [PDF]